A5101457577- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Cancer Genomics and Diagnostics
- Liver Disease and Transplantation
- Ultrasound and Hyperthermia Applications
- Hepatitis B Virus Studies
- Renal cell carcinoma treatment
- MRI in cancer diagnosis
- Neuroendocrine Tumor Research Advances
- Hepatitis C virus research
- Cancer, Hypoxia, and Metabolism
- Colorectal Cancer Treatments and Studies
- Pancreatitis Pathology and Treatment
- Cancer, Lipids, and Metabolism
- Liver physiology and pathology
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Photoacoustic and Ultrasonic Imaging
Yokohama City University
2009-2025
Yokohama City University Medical Center
2009-2025
Kanagawa Prefectural Hospital Organization
2015-2024
Kanagawa Cancer Center
2015-2024
Seoul National University Hospital
2020
Hyogo Prefectural Nishinomiya Hospital
2016-2018
Yokohama City University Hospital
2017
Sapienza University of Rome
2011
University of Kochi
2011
Azienda Ospedaliera San Gerardo
2011
To improve the efficacy of radiofrequency ablation (RFA) for treatment intermediate-sized hepatocellular carcinomas (HCCs), authors compared RFA combined with transcatheter arterial chemoembolization (TACE) to alone.The randomly assigned 37 patients solitary HCCs (diameter, 3.1-5.0 cm in greatest dimension) 2 groups: TACE-RFA group, which received TACE followed by on same day, and only RFA.Technical success was achieved after 1.4±0.5 sessions group 1.1±0.2 (P<.01). The mean diameters longer...
BackgroundIn the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a four-year updated OS analysis of HIMALAYA.Patients and methodsParticipants with uHCC no previous systemic treatment were randomized (n=393), (n=389), or (n=389). The data...
Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) Sor treatment HCC.We multicenter open-labeled randomized phase II in chemo-naïve patients HCC Child-Pugh scores 5-7. Eligible were randomly assigned 2:1 receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m2, day 1, every 4-6 weeks) or (400 bid). The primary end point...
<b><i>Introduction:</i></b> Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher activity is expected for the combination treatment. The aim of this trial was to evaluate efficacy safety in HAIC using patients HCC. <b><i>Methods:</i></b> In multicenter, open-labeled, single-arm, phase II trial, HCC categorized as Child-Pugh class A...
To determine whether radiographic images after radiofrequency (RF)-induced coagulation necrosis are correlated with the pathologic effects, we evaluated morphology and histologic characteristics of RF ablation lesions over a 6-month follow-up period compared results those radiologic studies. Thirty-three hepatocellular carcinoma (HCC) tumors maximum diameter 3 cm or less were treated percutaneously by using in 26 patients. Six resected 4 weeks ablation; remaining 27 underwent biopsy...
We evaluated the efficacy of fusion imaging that fuses conventional sonography images with hepatobiliary phase contrast-enhanced MR obtained gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) as reference image for detection hepatocellular carcinomas (HCCs).Eighty-seven HCCs a maximum diameter between 1 and 3 cm at time diagnosis were enrolled in this prospective study. compared rates using three modalities: sonography, late Sonazoid, combining MRI Gd-EOB-DTPA image....
Background: Low skeletal muscle mass is significantly associated with severe adverse events (AEs) from chemotherapy, and low tolerability leads to decreased survival. We aimed investigate whether body correlated prognosis in patients hepatocellular carcinoma (HCC) treated lenvatinib. Methods: This multicenter, retrospective study was conducted at five locations Japan. included 100 HCC Skeletal measured by computed tomography normalized for height m2 as index (SMI). The assessment criteria...
Abstract Background The efficacy of hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) remains unclear. We conducted a multi-center randomized phase II study comparing sequential HAIC-sorafenib regimen versus sorafenib alone as an initial therapy HCC. Methods Patients were randomly assigned (ratio, 1:1) to receive HAIC with cisplatin followed by (HAIC group, n = 35) or (sorafenib 33) therapy. primary endpoint was the one-year survival rate. Secondary...
PURPOSE: To assess the accuracy of pattern-based classification contrast material–enhanced wideband harmonic gray-scale ultrasonographic (US) images in differential diagnosis hepatic tumors. MATERIALS AND METHODS: A total 183 lesions patients were studied; included 116 hepatocellular carcinomas, 42 liver metastases, and 25 hemangiomas. After injection a galactose–palmitic acid agent, scanned with contrast-enhanced US arterial, portal venous, late venous phases. The enhancement patterns...
We evaluated the usefulness of contrast-enhanced harmonic gray scale sonography with a newly developed sonographic contrast medium as means guidance for percutaneous ablation therapy hepatocellular carcinoma lesions not detected by conventional sonography.We examined 85 patients 108 that were identified hypervascular multidetector-row computed tomography using after injection Sonazoid (GE Healthcare, Oslo, Norway), lipid-stabilized suspension perfluorobutane gas microbubble agent. scanned...
Aim: Sorafenib is approved for the treatment of advanced hepatocellular carcinoma (HCC) in Japan; however, its tolerability and efficacy elderly patients with HCC have not been clarified. We aimed to evaluate sorafenib increasing age. Methods: As part a retrospective, multicenter cohort study conducted between May 2009 February 2010, received 400 mg twice daily (standard dosage) or once (half‐dosage) until disease progression intolerance. Results: The mean age enrolled ( n = 76) was 70.3...
We describe our experience with the application of a novel technology in which fluoroscopy and 3D imaging from C-arm cone beam CT systems are combined integrated navigation software.We applied this to five cases radiofrequency ablation was performed for hepatocellular carcinoma. Technical success achieved without treatment-related complications all cases. conclude that is potentially useful targeting hepatic lesions.
Abstract Background This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE epirubicin regarding overall survival (OS) in patients unresectable hepatocellular carcinoma (HCC). Methods Patients HCC were randomized 1:1 to receive or lipiodol. The primary endpoint was OS; secondary endpoints percentages who achieved treatment effect (TE) 4 (100% necrotizing tumor reduction), duration time failure, and adverse events (AEs). OS...
Objective We evaluated the safety and efficacy of vonoprazan-based amoxicillin clarithromycin 7-day triple therapy (VAC) in comparison to proton pump inhibitor (PPI)-based (PAC) as a first-line treatment metronidazole (VAM) PPI-based (PAM) second-line for eradication Helicobacter pylori Japan.
To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).Patients u-HCC who were treated at multiple centers Japan retrospectively analyzed for outcomes according their respective CP status. Radiological objective response (OR) was assessed using modified evaluation criteria solid tumors (mRECIST) guidelines.Baseline demographic parameters...
Predictive biomarkers of the response hepatocellular carcinoma (HCC) to Lenvatinib therapy have not yet been clarified. The aim this study was identify clinically significant therapy, target strategies against HCC. Levels circulating angiogenic factors (CAFs) were analyzed in blood samples collected at baseline and after introducing lenvatinib, from 74 Child-Pugh class A HCC patients who received lenvatinib. As CAF biomarkers, serum vascular endothelial growth factor (VEGF), fibroblast 19...
A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c-Met inhibitor tivantinib as second-line treatment significantly prolonged progression-free survival in a subpopulation whose tumor samples highly expressed (MET-high). Accordingly, this 3 was conducted to evaluate efficacy for Japanese patients with MET-high carcinoma. This randomized, double-blind, placebo-controlled at 60 centers Japan. Hepatocellular one prior sorafenib and those were eligible inclusion....
To assess the impact of clinical factors on safety and efficacy atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u-HCC).Ninety-four u-HCC who were treated ATZ BV at multiple centers enrolled. We defined Child-Pugh (CP)-A received as a first line therapy 'meets broad sense IMbrave150 criteria' group (B-IMbrave150-in, n = 46), later or CP-B (regardless whether was therapy) B-IMbrave150-out (n 48). Patients retrospectively analyzed for...
We evaluated the usefulness of contrast-enhanced, wide-band harmonic gray scale imaging for diagnosis hepatocellular carcinoma and compared it with helical computed tomography. Forty-eight patients 61 lesions were scanned by after an intravenous bolus injection contrast agent Levovist. Fifty-seven showed hypervascular enhancement, intratumoral vessels could be observed in 40 57 lesions. Helical tomography revealed a high-attenuation area 54 lesions, whereas other equivocal-attenuation area....